The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.
AHA 2020 The OMEMI trial found no beneficial effects on CV outcomes and all-cause death by omega-3 fatty acid supplementation in elderly patients after MI, compared to patients receiving placebo.
AHA 2020 The nonsteroidal MRA finerenone, evaluated in the FIDELIO-DKD trial, reduced the risk on renal and CV outcome compared to placebo in CKD and T2DM patients with or without a history of CVD.
AHA 2020 In individuals with intermediate CV risk and without CVD history, a combination of polypill plus aspirin reduced the primary outcome of CVD events compared to double placebo.
AHA 2020 The STRENGTH trial found that omega-3 carboxylic acid supplementation had no beneficiary MACE outcome in patients with established or high-risk of CVD compared to placebo.
AHA 2020 The SAMSON trial showed that 90% of symptom burden in patients who previously discontinued statins is elicited by placebo tablets.
AHA 2020 Although the primary endpoint was just missed in the AFFIRM-AHF trial, the individual endpoint of total HF hospitalization was reduced by IV ferric carboxymaltose compared to placebo in patients with acute HF and iron deficiency.
AHA 2020 Prevalence of CAD in a Swedish population was 4 out of 10, using CCTA data from the SCAPIS cohort. A prediction model was developed to identify those with widespread atherosclerosis.
There are barriers to intensify treatment in T2DM patients leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.
In a prospective study using data of a large French cohort, high consumption of sugary drinks and artificially-sweetened beverages increased risk of CVD.
A protein-based risk prediction model significantly improved CV risk assessment compared to a clinical risk model with traditional risk factors in a setting of primary prevention, especially in the first 3 years.
In the GARFIELD-AF registry, most AF patients received recommended doses of NOAC. Those with nonrecommended doses (underdosing or overdosing) had increased risk of mortality compared to those with recommended doses.